BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests Adaptimmune to lay off up to 30% of staff as allogeneic ambitions stunted by cell line change ADC's accelerated review troubles signal FDA's tough new stance on confirmatory studies Amid 'biotech winter,' Insilico turns up the heat with Sanofi deal worth $1.2B in biobucks GSK hep B treatment’s efficacy slips 60% in full phase 2 readout, but phase 3 going ahead Zenas zips up $118M to launch phase 3 for rare autoimmune disease candidate Galecto posts GULLIVER-2 data to travel deeper into severe liver disease | 